Senators question Pfizer's partnership with UpScriptHealth, citing potential anti-kickback concerns and risks of increased ...

Pfizer's strong fundamentals, impressive R&D achievements, and undervalued metrics underscore its defensive appeal and growth ...

John Kenney Jr., MD, Lifetime Achievement Award and Lectureship recipient Pearl E. Grimes, MD, FAAD, delivered a tribute to her predecessor as she discussed the history and advancements of vitiligo.

The Medicare Part D redesign under the Inflation Reduction Act (IRA) is also expected to hurt sales of Pfizer’s higher-priced drugs like Vyndaqel, Ibrance and Xeljanz in 2025. However ...

Pfizer’s PFE stock has risen 5.9% in the past three months. The stock has started to show a consistent increase, with some ...

If approved, etrasimod will also have to compete with other oral UC drugs like Pfizer's JAK inhibitor Xeljanz (tofacitinib), although the entire JAK class is under a cloud because of safety ...

It will reach the market later this month with the task of taking on Pfizer’s first-to-market Xeljanz (tofacitinib) and Eli Lilly’s Olumiant (baricitinib), which are both approved for RA.

Acquired from Pfizer for $14 million ... I forget what jacket was, tofacitinib, And all of the class got slapped with black box labels. And at the time, RINVOC was a $3,000,000,000 drug that ...